Get startedLog in
    Picture of Sanofi SA logo

    SAN — Sanofi SA News Story

    0.000.00%
    fr flag iconLast trade - 00:00
    HealthcareBalancedLarge CapSuper Stock
    All News

    Brief: Sanofi Announces Decision Not To Submit Amlitelimab In Atopic Dermatitis For Global Regulatory Reviews

    Picture of Sanofi SA logoSanofi SA
    24/07/2026 06:34
    BRIEF-Sanofi Announces Decision Not To Submit Amlitelimab In Atopic Dermatitis For Global Regulatory Reviews
    July 24 (Reuters) - Sanofi SA SASY.PA:
    • SANOFI ANNOUNCES DECISION NOT TO SUBMIT AMLITELIMAB IN ATOPIC DERMATITIS FOR GLOBAL REGULATORY REVIEWS
    • DISCONTINUES CLINICAL DEVELOPMENT OF AMLITELIMAB IN ATOPIC DERMATITIS
    • WILL NOT SUBMIT AMLITELIMAB IN ATOPIC DERMATITIS FOR GLOBAL REGULATORY REVIEWS
    • SAYS EFFICACY AND SAFETY DATA DO NOT SUPPORT FURTHER AMLITELIMAB DEVELOPMENT IN ATOPIC DERMATITIS
    • NOT AMENDING ITS FULL-YEAR 2026 GUIDANCE AS A RESULT OF THIS ANNOUNCEMENT.
    • PHASE 2 STUDY OF AMLITELIMAB IN CELIAC DISEASE IS ONGOING AND EXPECTED TO READOUT IN SECOND HALF OF 2026
    Source text: nGNEcfpcKL
    Further company coverage: SASY.PA

     (Gdansk Newsroom)
     ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))

    Recent news on Sanofi SA

    See all news